Orthocell has announced its application to market and sell its leading guided bone and tissue repair product Striate+™ in Singapore, has been accepted for review by Health Services Authority of Singapore (HSA).
Proactive | Interview with Paul Anderson
Following the announcement that Orthocell is accelerating its global market expansion of Striate+™ and Remplir™, Managing Director Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s seven regulatory applications in progress or planned, targeting approval in significant markets.
Paul spoke of the positive feedback from clinicians on Orthocell’s innovative regenerative medicine products and plans to capture a meaningful share of the global market as part of the Company’s growth strategy.
“Orthocell has always focused on providing solutions for clinicians. When you combine those that are available to us, from both our dental bone product and our nerve product, we’re talking about $3 billion a year in addressable markets. We’re very confident, given the outstanding uptake that we’ve seen for both Striate+ and Remplir, that we can drive towards a 20% market share of that market. And we think that we can do that with our partners, in conjunction with the excellent product and education that we provide to surgeons internationally.”
Orthocell Accelerates Global Market Expansion of Striate+™ and Remplir™ With Seven New Regulatory Applications either in progress or planned
Orthocell has announced the accelerated market expansion of Striate+™ and Remplir™, with seven regulatory applications either in progress or planned for its medical device platform products.
Orthocell Receives Regulatory Approval to Commence Sales of Striate+™ in Canada
Orthocell has received a Medical Device Licence from Health Canada, allowing the commencement of sales of its market leading dental guided bone regeneration product, Striate+™, in the key market of Canada.
The Australian Business Review | Investors are all ears as Orthocell’s nerve and tissue solutions deliver record revenue
News of Orthocell’s record-breaking quarterly and full year revenue has been published in a Special Report in The Australian Business Review.
Business News | Orthocell posts record revenue
Orthocell’s record revenue for FY24 has been reported in Business News.
Proactive Interview | Record-breaking revenue for FY24
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to discuss the Company’s record-breaking revenue for the June 24 quarter and for FY24.
Orthocell Continues Impressive Growth with Record Quarterly and Yearly Revenue Achieved
Orthocell has announced that it has recorded impressive sales growth across its product portfolio, with total revenue for FY24 of $6.72million – up 30.40% from the previous financial year, FY23.
Petra Capital Research Report | June 2024
Petra Capital has released research report, forecasting Orthocell’s potential to reach A$1.28 per share.
Orthocell applies for TGA market approval for SmrtGraft™
Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraft™ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.